Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | ACHE | P22303 | 8/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.61 |
| ▸ | BCHE | P06276 | 3/20 | 0.56 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8476129 | 0.92 | HTT (0.73) | HTTGAAMAPTKMT2AACHE | |
| SCHEMBL9749208 | 0.87 | HTT (0.64) | HTTGAAMAPTKMT2AACHE | |
| SCHEMBL9208663 | 0.83 | HTT (0.74) | HTTGAAMAPTACHEBCHE | |
| SCHEMBL8473136 | 0.82 | HTT (0.69) | HTTGAAMAPTACHEHDAC6 | |
| SCHEMBL8472225 | 0.81 | HTT (0.71) | HTTGAAMAPTACHEBCHE | |
| SCHEMBL9747579 | 0.79 | BCHE (0.83) | HTTGAAMAPTKMT2AACHE | |
| SCHEMBL8474173 | 0.79 | BCHE (0.66) | HTTGAAMAPTACHEBCHE | |
| SCHEMBL9748781 | 0.78 | KDM4E (0.68) | HTTGAAMAPTKMT2AACHE | |
| SCHEMBL9382159 | 0.78 | KDM4E (0.65) | HTTGAAMAPTKMT2AACHE | |
| SCHEMBL9387187 | 0.77 | KDM4E (0.69) | HTTGAAMAPTKMT2AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1853920-B1 | FLUORESCENCE POLARIZATION ASSAYS FOR ACETYLTRANSFERASE/DEACETYLASE ACTIVITY | SIRTRIS PHARMACEUTICALS INC (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | ELIXIR PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | ELIXIR PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
| US-20090069301-A1 | Acridine and Quinoline Derivatives as Sirtuin Modulators | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069301-A1 | Acridine and Quinoline Derivatives as Sirtuin Modulators | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20080293081-A1 | Fluorescence Polarization Assays for Acetyltransferase/Deacetylase Activity | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293081-A1 | Fluorescence Polarization Assays for Acetyltransferase/Deacetylase Activity | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168084-A1 | Therapeutic compounds and related methods of use | EP300, KAT2A, KAT6B | HTT 36/4885GAA 119/4885MAPT 1946/4885 |
| US-20090069301-A1 | Acridine and Quinoline Derivatives as Sirtuin Modulators | SIRT1, SIRT3, SIRT2 | HTT 12/4885GAA 220/4885MAPT 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.